Evidence map›Paper›PMID 42350374›Full record

ReviewCell death discovery2026

Molecular diversity of mitochondrial autophagy receptors: context-dependent effects in human health and disease.

Ana Rožić, Mija Marinković, Ivana Novak

Abstract readReview
In one paragraph

Review in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ana RožićSchool of Medicine, University of Split, Split, Croatia.ORCID http://orcid.org/0000-0001-6371-069X
Mija MarinkovićFaculty of Science, University of Split, Split, Croatia. mmarinkov@pmfst.hr.ORCID http://orcid.org/0000-0002-8702-9126
Ivana NovakSchool of Medicine, University of Split, Split, Croatia. ivana.novak@mefst.hr.ORCID http://orcid.org/0000-0003-0682-7052

Funding

EC | European Regional Development Fund (Europski Fond za Regionalni Razvoj) STIM-REI 2.0 (PK.1.1.10.0005)Hrvatska Zaklada za Znanost (Croatian Science Foundation) IP-2020-02-3883, DOK-2021-02-4248Hrvatska Zaklada za Znanost (Croatian Science Foundation) UIP-2025-02-8501
6 · The paper itself

Abstract

Mitophagy receptors are central regulators of mitochondrial quality control, integrating metabolic, stress-related, and developmental cues to maintain cellular homeostasis. Accumulating evidence indicates that their dysregulation contributes to a broad spectrum of human diseases through highly context-dependent mechanisms. In cardiovascular and neurological disorders, receptor-mediated mitophagy shapes cell survival, synaptic function, stress adaptation, and tissue integrity, with both insufficient and excessive activity proving detrimental. In cancer, mitophagy receptors display dual and stage-specific roles, acting as tumor suppressors in early disease while later supporting metabolic adaptation, stemness, and therapy resistance. Metabolic diseases highlight the tissue-specific complexity of mitophagy regulation, where precise control of mitochondrial turnover is essential for insulin sensitivity, calcium signaling, and energy homeostasis. In hematological, inflammatory, and autoimmune disorders, receptor-mediated mitophagy emerges as a fundamental determinant of lineage commitment, immune cell function, and inflammatory balance. Collectively, these findings position mitophagy receptors not as uniform stress responders, but as dynamic modulators of disease progression, whose precise and context-sensitive targeting may offer novel therapeutic opportunities across diverse pathological conditions.

Identifiers

PMID42350374
PMCPMC13558601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.